These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 21249289)

  • 1. [Biomarkers for spondyloarthropathies. State of the art].
    Romero-Sánchez C; Londoño J; DE Avila J; Valle-Oñate R
    Rev Med Chil; 2010 Sep; 138(9):1179-85. PubMed ID: 21249289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cartilage biomarkers in ankylosing spondylitis: relationship to clinical variables and treatment response.
    Kim TH; Stone M; Payne U; Zhang X; Ionescu M; Lobanok T; King L; Poole AR; Inman RD
    Arthritis Rheum; 2005 Mar; 52(3):885-91. PubMed ID: 15751093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFα inhibitors.
    Pedersen SJ; Sørensen IJ; Garnero P; Johansen JS; Madsen OR; Tvede N; Hansen MS; Thamsborg G; Andersen LS; Majgaard O; Loft AG; Erlendsson J; Asmussen K; Jurik AG; Møller J; Hasselquist M; Mikkelsen D; Skjødt T; Lambert R; Hansen A; Østergaard M
    Ann Rheum Dis; 2011 Aug; 70(8):1375-81. PubMed ID: 21551511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers in spondyloarthropathies.
    Chen CH; Yu DT; Chou CT
    Adv Exp Med Biol; 2009; 649():122-32. PubMed ID: 19731625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.
    de Vries MK; van Eijk IC; van der Horst-Bruinsma IE; Peters MJ; Nurmohamed MT; Dijkmans BA; Hazenberg BP; Wolbink GJ
    Arthritis Rheum; 2009 Nov; 61(11):1484-90. PubMed ID: 19877087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble and tissue biomarkers in ankylosing spondylitis.
    de Vlam K
    Best Pract Res Clin Rheumatol; 2010 Oct; 24(5):671-82. PubMed ID: 21035087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis.
    Maksymowych WP; Poole AR; Hiebert L; Webb A; Ionescu M; Lobanok T; King L; Davis JC
    J Rheumatol; 2005 Oct; 32(10):1911-7. PubMed ID: 16206346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany].
    Brandt J; Westhoff G; Rudwaleit M; Listing J; Zink A; Braun J; Sieper J
    Z Rheumatol; 2003 Jun; 62(3):264-73. PubMed ID: 12827403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The reliability and validity of a Croatian version of the Bath Ankylosing Spondylitis Functional Index (BASFI) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in patients with ankylosing spondylitis].
    Grazio S; Grubisić F; Nemcić T; Matijević V; Skala H
    Reumatizam; 2009; 56(2):63-76. PubMed ID: 20429263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept.
    Woo JH; Lee HJ; Sung IH; Kim TH
    J Rheumatol; 2007 Aug; 34(8):1753-9. PubMed ID: 17610317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The BASDAI-D--an instrument to defining disease status in ankylosing spondylitis and related diseases].
    Bönisch A; Ehlebracht-König I
    Z Rheumatol; 2003 Jun; 62(3):251-63. PubMed ID: 12827402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis.
    Lukas C; Landewé R; Sieper J; Dougados M; Davis J; Braun J; van der Linden S; van der Heijde D;
    Ann Rheum Dis; 2009 Jan; 68(1):18-24. PubMed ID: 18625618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity.
    Chen CH; Lin KC; Yu DT; Yang C; Huang F; Chen HA; Liang TH; Liao HT; Tsai CY; Wei JC; Chou CT
    Rheumatology (Oxford); 2006 Apr; 45(4):414-20. PubMed ID: 16287916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
    Yang CH; Huang F; Deng XH; Zhang JL; Zhang LY; Guo JH; Liang DF; Wang LS; Zhang YM
    Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(35):2451-4. PubMed ID: 17156669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis.
    Spoorenberg A; van der Heijde D; de Klerk E; Dougados M; de Vlam K; Mielants H; van der Tempel H; van der Linden S
    J Rheumatol; 1999 Apr; 26(4):980-4. PubMed ID: 10229432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diurnal variation of serum and urine biomarkers in patients with radiographic knee osteoarthritis.
    Kong SY; Stabler TV; Criscione LG; Elliott AL; Jordan JM; Kraus VB
    Arthritis Rheum; 2006 Aug; 54(8):2496-504. PubMed ID: 16868970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Spondyloarthropathies--clinical evaluation and physical therapy].
    Vlak T
    Reumatizam; 2004; 51(2):29-33. PubMed ID: 15554374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis.
    van der Heijde D; Lie E; Kvien TK; Sieper J; Van den Bosch F; Listing J; Braun J; Landewé R;
    Ann Rheum Dis; 2009 Dec; 68(12):1811-8. PubMed ID: 19060001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of reducing infliximab dose interval in non-responder patients with refractory spondyloarthropathies. An open extension of a multicentre study.
    Collantes-Estevez E; Muñoz-Villanueva MC; Zarco P; Torre-Alonso JC; Gratacós J; González C; Sanmartí R; Cañete JD;
    Rheumatology (Oxford); 2005 Dec; 44(12):1555-8. PubMed ID: 16118228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucosamine sulfate and cartilage type II collagen degradation in patients with knee osteoarthritis: randomized discontinuation trial results employing biomarkers.
    Cibere J; Thorne A; Kopec JA; Singer J; Canvin J; Robinson DB; Pope J; Hong P; Grant E; Lobanok T; Ionescu M; Poole AR; Esdaile JM
    J Rheumatol; 2005 May; 32(5):896-902. PubMed ID: 15868627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.